Text Size

Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) (KLL3)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
MSinisalo, Tampere University Hospital
ClinicalTrials.gov Identifier:
NCT01397916
First received: May 18, 2010
Last updated: March 29, 2012
Last verified: March 2012
History of Changes
  Purpose

The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.


Condition
CLL

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Tampere University Hospital:

Primary Outcome Measures:
  • IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR.


Biospecimen Retention:   Samples With DNA

Ido expression


Enrollment: 73
Study Start Date: February 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
CLL-patients
Controls

Detailed Description:

The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.

  Eligibility

Ages Eligible for Study:   15 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients with CLL

Criteria

Inclusion Criteria:

  • Patients with CLL and lymphocyte count > 10 x 109/l

Exclusion Criteria:

  • Acute infection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01397916

Locations
Finland
Tampere university Hospital
Tampere, Finland, 33521
Sponsors and Collaborators
Tampere University Hospital
Investigators
Principal Investigator: Marjatta Sinisalo, MD, PhD Tampere University Hospital
  More Information

No publications provided

Responsible Party: MSinisalo, Dr, Tampere University Hospital
ClinicalTrials.gov Identifier: NCT01397916     History of Changes
Other Study ID Numbers: CLL-IDO
Study First Received: May 18, 2010
Last Updated: March 29, 2012
Health Authority: Finland: Finnish Medicines Agency

Keywords provided by Tampere University Hospital:
CLL
IDO

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
 Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 19, 2013